Preclinical and clinical evidence for the treatment of non-alcoholic fatty liver disease with soybean: A systematic review and meta-analysis

Non-alcoholic fatty liver disease (NAFLD), a prevalent public health issue, involves the accumulation of triglycerides in hepatocytes, which is generally considered to be an early lesion of liver fibrosis and cirrhosis. Thus, the development of treatments for NAFLD is urgently needed. This study explored the preclinical and clinical evidence of soybeans to alleviate NAFLD. Studies indexed in three relevant databases—Web of Science, PubMed, and Embase—between January 2002 and August 2022 were retrieved. A total of 13 preclinical studies and five RCTs that included 212 animals and 260 patients were included in the present analysis. The preclinical analysis showed that liver function indices (AST, SMD = −1.41, p < 0.0001 and ALT, SMD = −1.47, p < 0.0001) were significantly improved in the soybean group compared to the model group, and fatty liver indicators (TG, SMD = −0.78, p < 0.0001; TC, SMD = −1.38, p < 0.0001) and that oxidative stress indices (MDA, SMD = −1.09, p < 0.0001; SOD, SMD = 1.74, p = 0.022) were improved in the soybean group. However, the five RCTs were not entirely consistent with the preclinical results; however, the results confirmed the protective effect on the liver. The results of the clinical RCTs showed that soybean significantly affected liver function, fatty liver, and oxidative stress indicators (ALT, SMD = −0.42, p = 0.006; TG, SMD = −0.31, p = 0.039; MDA, SMD = −0.76, p = 0.007). The current meta-analysis combined preclinical and clinical studies and verified that soybean could protect the liver in NAFLD by regulating lipid metabolism and oxidative stress factors via the Akt/AMPK/PPARα signaling pathway. Soybean might be a promising therapeutic agent for treating non-alcoholic fatty liver disease. Systematic Review Registration: (https://www.crd.york.ac.uk/prospero/#myprospero), identifier (CRD42022335822).

[1]  H. Qin,et al.  Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations , 2022, Signal Transduction and Targeted Therapy.

[2]  Xichang Wang,et al.  Comparison of Egg Yolk and Soybean Phospholipids on Hepatic Fatty Acid Profile and Liver Protection in Rats Fed a High-Fructose Diet , 2021, Foods.

[3]  V. Wong,et al.  Non-alcoholic fatty liver disease , 2021, The Lancet.

[4]  Doyoung Kwon,et al.  Germinated Soybean Embryo Extract Ameliorates Fatty Liver Injury in High-Fat Diet-Fed Obese Mice , 2020, Pharmaceuticals.

[5]  S. Gleddie,et al.  Soybean Bioactive Peptides and Their Functional Properties , 2018, Nutrients.

[6]  L. Boccuto,et al.  Health benefits of Mediterranean diet in nonalcoholic fatty liver disease , 2018, Expert review of gastroenterology & hepatology.

[7]  Wei Chen,et al.  Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A2 Pathway. , 2018, Journal of agricultural and food chemistry.

[8]  R. Parker.  The role of adipose tissue in fatty liver diseases , 2018 .

[9]  Chi-Tang Ho,et al.  Anti-obesity molecular mechanism of soy isoflavones: weaving the way to new therapeutic routes. , 2017, Food & function.

[10]  G. Steinberg,et al.  AMPK as a Therapeutic Target for Treating Metabolic Diseases , 2017, Trends in Endocrinology & Metabolism.

[11]  E. Krul,et al.  Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats. , 2017, The Journal of nutritional biochemistry.

[12]  Huanhuan Liu,et al.  Effects of soy isoflavone on hepatic steatosis in high fat-induced rats , 2017, Journal of clinical biochemistry and nutrition.

[13]  S. Friend,et al.  Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes , 2017, Science Translational Medicine.

[14]  Qing-Wen Zhang,et al.  The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats. , 2016, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[15]  H. Krishnan,et al.  Soy and Gut Microbiota: Interaction and Implication for Human Health. , 2016, Journal of agricultural and food chemistry.

[16]  H. Ashktorab,et al.  Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations , 2016, Digestive Diseases and Sciences.

[17]  H. Sul,et al.  Transcriptional regulation of hepatic lipogenesis , 2015, Nature Reviews Molecular Cell Biology.

[18]  Y. Ilan,et al.  Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance. , 2015, World journal of gastroenterology.

[19]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[20]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[21]  T. Yanagita,et al.  Soy β-conglycinin improves obesity-induced metabolic abnormalities in a rat model of nonalcoholic fatty liver disease. , 2015, Obesity research & clinical practice.

[22]  J. Jeong,et al.  Beneficial effects of phosphatidylcholine on high-fat diet-induced obesity, hyperlipidemia and fatty liver in mice. , 2014, Life sciences.

[23]  L. Rui,et al.  Energy metabolism in the liver. , 2014, Comprehensive Physiology.

[24]  D. Hum,et al.  Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.

[25]  Hyun-Sook Kim,et al.  The inhibitory effect of black soybean on hepatic cholesterol accumulation in high cholesterol and high fat diet-induced non-alcoholic fatty liver disease. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[26]  Kozo Matsumoto,et al.  Genetic Dissection of Complex Genetic Factor Involved in NIDDM of OLETF Rat , 2012, Experimental diabetes research.

[27]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[28]  J. Kim,et al.  Protective Effect of Proanthocyanidin against Diabetic Oxidative Stress , 2011, Evidence-based complementary and alternative medicine : eCAM.

[29]  Jiun-Rong Chen,et al.  Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis. , 2011, Nutrition.

[30]  K. Gumireddy,et al.  Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. , 2005, Diabetes.

[31]  R. Robertson,et al.  β-Cell Glucose Toxicity, Lipotoxicity, and Chronic Oxidative Stress in Type 2 Diabetes , 2004 .

[32]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[33]  V. Manganiello,et al.  Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. , 2002, Diabetes.

[34]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[35]  R. Bergman,et al.  Extreme insulin resistance of the central adipose depot in vivo. , 2002, Diabetes.

[36]  L Wood,et al.  Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. , 2001, American journal of physiology. Endocrinology and metabolism.

[37]  A. Mizuno,et al.  Pathoetiology and prevention of NIDDM lessons from the OLETF rat. , 1999, The journal of medical investigation : JMI.

[38]  A. Frydén,et al.  The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. , 1999, Scandinavian journal of gastroenterology.

[39]  J. Peters,et al.  Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor α and γ Activators in a Tissue- and Inducer-specific Manner* , 1998, The Journal of Biological Chemistry.

[40]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[41]  D. Hardie,et al.  Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. , 1996, The American journal of physiology.

[42]  M. Tsai,et al.  Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. , 2014, Molecular Nutrition & Food Research.

[43]  R. Robertson,et al.  Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. , 2004, Diabetes.

[44]  T. Willson,et al.  Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. , 2001, The Biochemical journal.

[45]  J. Peters,et al.  Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. , 1998, The Journal of biological chemistry.